SCHEMBL2581063

SCHEMBL2581063

COc1cccc(-c2ccc(C=O)cc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 1/20 0.64
ALDH1A1 P00352 2/20 0.57
CYP2A6 P11509 2/20 0.57
ERN1 O75460 1/20 0.54
ABL1 P00519 2/20 0.53
ABCB1 P08183 2/20 0.53
BCR P11274 2/20 0.53
MAOB P27338 2/20 0.53
HDAC4 P56524 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
BRD4 O60885 1/20 0.51
CYP1A1 P04798 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2E1 P05181 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C8 P10632 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP4B1 P13584 1/20 0.50
CYP2B6 P20813 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3804053 0.89 ALDH1A1 (0.58) DRD1ALDH1A1CYP2A6ERN1ABL1
SCHEMBL2591901 0.87 ERN1 (0.55) DRD1ALDH1A1CYP2A6ERN1HDAC4
SCHEMBL4154213 0.85 ABL1 (0.56) DRD1CYP2A6ABL1ABCB1BCR
SCHEMBL1180343 0.84 ABL1 (0.69) ALDH1A1CYP2A6ABL1ABCB1BCR
SCHEMBL1977748 0.82 ABL1 (0.58) DRD1ALDH1A1CYP2A6ERN1ABL1
SCHEMBL32688276 0.82 ABL1 (0.58) DRD1ALDH1A1CYP2A6ERN1ABL1
SCHEMBL1483077 0.82 ABL1 (0.53) CYP2A6ABL1ABCB1BCRMAOB
SCHEMBL1483075 0.82 ABL1 (0.53) DRD1CYP2A6ABL1ABCB1BCR
SCHEMBL2623451 0.82 DRD1 (0.49) DRD1ALDH1A1CYP2A6ERN1ABL1
SCHEMBL17157579 0.81 RXRA (0.61) DRD1ALDH1A1BRD4CYP3A4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 US disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 US disclosed
WO-2011135303-A2 UBIQUITINATION MODULATORS ITI SCOTLAND LIMITED (GB) 2011-11-03 WO disclosed
WO-2011135303-A2 UBIQUITINATION MODULATORS ITI SCOTLAND LIMITED (GB) 2011-11-03 WO disclosed
US-20100216762-A1 Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof ABBOTT LABORATORIES (US) 2010-08-26 US disclosed
US-20100216762-A1 Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof ABBOTT LABORATORIES (US) 2010-08-26 US disclosed
WO-2010093704-A1 AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF ABBOTT LABORATORIES (US) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK DRD1 2857/4885ALDH1A1 3674/4885CYP2A6 3749/4885
US-20100216762-A1 Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof S1PR5, LPAR5, S1PR1 DRD1 821/4885ALDH1A1 1328/4885CYP2A6 3123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.